Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Ritonavir on BMS-986165 Pharmacokinetics in Healthy Participants
NCT04055506Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 1, Area under the plasma concentration-time curve from time zero to last quantifiable concentration at Day 1 and 1 more. Started Aug 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04055506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055506.